Marburg Vaccine Shows Promising Results in First-In-Human Study

January 31, 2023 by TWN Staff
Marburg Vaccine Shows Promising Results in First-In-Human Study
Colorized scanning electron micrograph of Marburg virus particles (blue) both budding and attached to the surface of infected VERO E6 cells (orange). (NIH photo)

WASHINGTON — An experimental vaccine against Marburg virus, a member of the Ebola virus family that causes death in a large proportion of infected individuals, proved safe and induced an immune response in a small, first-in-human clinical trial.

The findings of the researchers at the National Institute of Allergy and Infectious Diseases were published in The Lancet.

According to their paper, the experimental MARV vaccine candidate, known as cAd3-Marburg, was developed at NIAID’s Vaccine Research Center using a modified chimpanzee adenovirus called cAd3, which can no longer replicate or infect cells.

The cAd3 vaccine platform demonstrated a good safety profile in prior clinical trials when used in investigational Ebola virus and Sudan virus vaccines developed by the VRC.

According to a press release on the National Institutes of Health website, many scientists believe MARV disease outbreaks in humans begin when the virus makes the jump from its primary animal host, which is likely to be certain chronically infected bats in sub-Saharan Africa. 

The symptoms of MARV disease are akin to those seen with Ebola virus disease and can include fever, headache, chills, rash, abdominal pain, vomiting and diarrhea. 

As the disease progresses, the release said, patients may suffer from multiple organ dysfunction, delirium and significant bleeding from the gastrointestinal tract or other sites that may result in death. 

No approved vaccines or specific therapies are available for MARV disease, aside from supportive care. 

While some experimental vaccines have previously been tested, none have proven to be both highly effective and to provide durable protection. In areas of Africa where a vaccine for Marburg is most needed, a single-dose vaccine that could protect recipients over a long period of time would be a crucial part of quelling outbreaks.

In this study, 40 healthy adult volunteers were enrolled at the Walter Reed Army Institute of Research Clinical Trials Center in Silver Spring, Maryland. 

They received a single dose of either a low dose of the vaccine (1×1010 particle units) or a higher dose (1×1011 particle units). For safety, the volunteers were enrolled in a dose-escalation plan. 

Three participants received the lower dose. Then, when they did not exhibit severe adverse reactions after the first seven days, the trial proceeded to enroll the remaining 17 volunteers. The same procedure was also used for the higher dose group. Volunteers were monitored for adverse reactions to the investigational vaccine and evaluated at regular intervals for 48 weeks to track their immune responses.

The trial’s safety results were encouraging: There were no serious adverse events and the experimental vaccine was well-tolerated. One participant in the higher dose group developed a fever following vaccination, but it resolved by the following day. 

In addition, the investigational vaccine appeared to induce strong, long-lasting immunity to the MARV glycoprotein: 95% of participants in the trial exhibited a robust antibody response after vaccination, and 70% maintained that response for more than 48 weeks.

Plans are in place to conduct further trials of the cAd3-Marburg vaccine in Ghana, Kenya, Uganda and the United States. If additional data supports the promising results seen in the phase 1 trial, the cAd3-Marburg virus vaccine could someday be used in emergency responses to MARV outbreaks, the institute’s release said.

Dan can be reached at [email protected] and @DanMcCue

A+
a-
  • Ebola virus
  • Marburg
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health
  • In The News

    Health

    Voting

    Research

    November 7, 2023
    by Jesse Zucker
    Getting Quality Sleep Impacts Health and Fitness

    WASHINGTON — We’ve all woken up feeling groggy and dreading the day ahead. When you’re busy and stressed, it’s hard... Read More

    WASHINGTON — We’ve all woken up feeling groggy and dreading the day ahead. When you’re busy and stressed, it’s hard to get to bed early. Even if you manage an early bedtime, sometimes you can’t fall asleep. The CDC states that 33% of adults sleep less... Read More

    Mind-Altering Ketamine Becomes Latest Pain Treatment, Despite Little Research

    WASHINGTON (AP) — As U.S. doctors scale back their use of opioid painkillers, a new option for hard-to-treat pain is taking... Read More

    WASHINGTON (AP) — As U.S. doctors scale back their use of opioid painkillers, a new option for hard-to-treat pain is taking root: ketamine, the decades-old surgical drug that is now a trendy psychedelic therapy. Prescriptions for ketamine have soared in recent years, driven by for-profit clinics and telehealth... Read More

    AI Raises Fears About Risks to Humanity. Are Tech and Political Leaders Doing Enough?

    LONDON (AP) — Chatbots like ChatGPT wowed the world with their ability to write speeches, plan vacations or hold a conversation as good... Read More

    LONDON (AP) — Chatbots like ChatGPT wowed the world with their ability to write speeches, plan vacations or hold a conversation as good as or arguably even better than humans do, thanks to cutting-edge artificial intelligence systems. Now, frontier AI has become the latest buzzword as concerns grow that... Read More

    October 18, 2023
    by Dan McCue
    FDA Establishes New Advisory Committee on Digital Health Technologies

    WASHINGTON — The Food and Drug Administration is creating a new Digital Health Advisory Committee to help the agency assess... Read More

    WASHINGTON — The Food and Drug Administration is creating a new Digital Health Advisory Committee to help the agency assess and deal with the complex scientific and technical issues related to the burgeoning market of new digital health technologies. These technologies include everything from artificial intelligence... Read More

    Are 3D Mammograms Better Than Standard Imaging? Diverse Study Aims to Find Out

    Are 3D mammograms better than standard 2D imaging for catching advanced cancers? A clinical trial is recruiting thousands of volunteers — including... Read More

    Are 3D mammograms better than standard 2D imaging for catching advanced cancers? A clinical trial is recruiting thousands of volunteers — including a large number of Black women who face disparities in breast cancer death rates — to try to find out. People like Carole Stovall, a psychologist... Read More

    September 27, 2023
    by Dan McCue
    Nearly 7% of Americans Say They Have Had Long COVID

    ATLANTA — Nearly 7% of Americans participating in a new survey said they’ve had long COVID in the past year,... Read More

    ATLANTA — Nearly 7% of Americans participating in a new survey said they’ve had long COVID in the past year, and 3.4% said they had it “currently,” according to the Centers for Disease Control and Prevention's National Center for Health Statistics. In a series of related... Read More

    News From The Well
    scroll top